2016 FDA Warning Letters: Top Takeaways (So Far)

Panelists at SupplySide Global 2026 discussed protein's limits, shifting supplement formats, clean-label expectations, and plainer ingredient communication.

AHPA, CHPA, CRN, and UNPA say placing ODS under the Office of Nutrition Research would add a layer of bureaucracy. NIH is accepting comments through October 28.

Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.

FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.

The agency’s editorial identifies needs across six areas, including new methods for novel products, gut microbiome data, and AI-supported risk assessment.

The Council for Responsible Nutrition says its Morning Consult survey also found that three in four adults use supplements and that cost is the most commonly cited barrier.

The proposed notification requirement is straightforward, but its legal and commercial consequences are not.

The four-formula line is Olly’s second retailer-exclusive launch this year, following the launch of a probiotic range in April.